Stockscreener 앱 받기
78.00
3.31%
-2.67
시간 외 거래:
79.75
1.75
+2.24%
전일 마감가:
$80.67
열려 있는:
$80
하루 거래량:
40,443
Relative Volume:
0.08
시가총액:
$83.49M
수익:
$7.10M
순이익/손실:
$-39.43M
주가수익비율:
-82.98
EPS:
-0.94
순현금흐름:
$-46.50M
1주 성능:
-18.02%
1개월 성능:
-26.65%
6개월 성능:
-86.69%
1년 성능:
-90.34%
1일 변동 폭
$75.21
$82.40
1주일 범위
$75.21
$95.05
52주 변동 폭
$7.26
$543.38
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
SPRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
78.00 | 86.35M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-03-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 개시 | Guggenheim | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directo - PharmiWeb.com
Spruce Biosciences appoints Keli Walbert to board of directors - marketscreener.com
Spruce Biosciences Appoints Keli Walbert To Board Of Directors - TradingView — Track All Markets
Spruce Biosciences Appoints Keli Walbert as Director - TipRanks
Spruce Biosciences (NASDAQ: SPRB) names rare-disease veteran Keli Walbert to board - Stock Titan
Wall Street Zen Upgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - MarketBeat
Spruce Biosciences (SPRB) Price Target Increased by 55.76% to 213.69 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Raised to Strong-Buy at Leerink Partnrs - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Leerink Partners Upgrades Spruce Biosciences (SPRB) - Nasdaq
Spruce Biosciences Shares Rise After Upgrade From Leerink - marketscreener.com
SPRB: Leerink Partners Upgrades to Outperform with $160 Target | - GuruFocus
Leerink Partners upgrades Spruce Biosciences stock to Outperform By Investing.com - Investing.com Canada
Leerink Partners upgrades Spruce Biosciences stock to Outperform - Investing.com
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Spruce Biosciences (SPRB) Price Target Increased by 2,045.14% to 137.19 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Is Spruce Biosciences Stock Built to Withstand More Downside? - Trefis
Citizens Jmp Forecasts Strong Price Appreciation for Spruce Biosciences (NASDAQ:SPRB) Stock - MarketBeat
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy - Investing.com Australia
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy By Investing.com - Investing.com South Africa
Citizens Maintains Spruce Biosciences (SPRB) Market Outperform Recommendation - Nasdaq
SPRB: Citizens Raises Price Target for Spruce Biosciences | SPRB Stock News - GuruFocus
Spruce Biosciences Reports Q3 2025 Financial Results - TipRanks
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
SPRB Announces Key Financing Milestones and Regulatory Achieveme - GuruFocus
Spruce Biosciences Q3 net loss narrows - MarketScreener
Spruce Biosciences Inc expected to post a loss of $13.93 a shareEarnings Preview - TradingView
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - MarketBeat
One new option listing and two option delistings on September 5th - MSN
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Spruce Biosciences (SPRB) Price Target Decreased by 37.30% to 6.40 - MSN
[S-3] SPRUCE BIOSCIENCES, INC. Shelf Registration Statement | SPRB SEC FilingForm S-3 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Brokerages - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Citizens Jmp - MarketBeat
Spruce Biosciences Stock Rallied 1184%Have You Assessed the Risk - Trefis
JMP Securities Upgrades Spruce Biosciences (SPRB) - Nasdaq
Cash per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
SPRB: JMP Securities Upgrades Spruce Biosciences to Market Outpe - GuruFocus
Spruce Biosciences Raised to Market Outperform From Market Perform by JMP Securities - 富途牛牛
Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Stock Dropped 16%Have You Assessed the Risk - Trefis
Spruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Zacks Research - MarketBeat
What is Leerink Partnrs' Forecast for SPRB FY2025 Earnings? - MarketBeat
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire
Spruce Biosciences Announces $50 Million Private Placement Financing - Global Legal Chronicle
Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan
SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan
The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - Healthcare Brew
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
스프루스 바이오 주식 (SPRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
0.39%
1.90%
자본화:
|
볼륨(24시간):